All articles tagged with #trial results
Shares of Ultragenyx and Mereo BioPharma plummeted after their Phase 3 trial for the brittle-bone disease treatment setrusumab failed to meet primary endpoints, despite secondary improvements in bone density, leading to significant market value losses and cautious outlooks from analysts.
Eli Lilly announced that its anti-obesity pill, orforglipron, successfully met weight-loss targets in a key diabetes trial, reducing body weight by 10.5% on average, which boosts its plans for FDA approval and intensifies competition with Novo Nordisk in the weight-loss drug market.
Eli Lilly's obesity drug underperformed in clinical trials, leading to a 14% drop in its shares, disappointing investors and raising concerns about its future prospects.
Amgen's shares dropped after disappointing trial results for its weight-loss drug MariTide, which showed high discontinuation rates due to gastrointestinal side effects, especially at higher doses, despite promising efficacy in weight loss; the company plans to adjust its Phase 3 trial strategy to mitigate these issues.
Novo Nordisk, the maker of the weight-loss drug Wegovy, shared data from a major trial showing that the drug lowers the risk of adverse cardiovascular events by 20%. The trial involved over 17,000 participants and measured data over a five-year period. The 2.4 mg dosage of Wegovy was found to be safe and well-tolerated. The announcement of the trial results caused Novo Nordisk's shares to surge by over 16%.